CClinicalTrials.gg
RecruitingNCT05960370CompactionUpdated Oct 3, 2024

Impact of Endometrial Compaction on Reproductive Outcomes After Cryotransfer of Euploid Embryos in a Natural Cycle

An observational study in Infertility Due to Nonimplantation, sponsored by Instituto Bernabeu. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Instituto Bernabeu · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
206
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Multicenter prospective observational cohort study, comparing ongoing pregnancy rates in natural cycles for euploid embryo transfer in patients who present endometrial compaction at the time of the transfer versus those who have a stable or greater endometrial thickness with respect to the estrogenic phase.

Read the detailed description

Multicenter prospective observational cohort study. Based on our sample size calculation, the study group will consist of 206 women (exposed or "compaction" group: 103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase and the day of embryo transfer; non-exposed "non-compaction" group: 103 women with similar or greater endometrial thickness between these time points). The main objective of this study is to compare the ongoing pregnancy rates in natural cycles for euploid embryo transfer in patients who present endometrial compaction at the time of transfer versus those who with a stable or greater endometrial thickness with respect to the estrogenic phase. The estimated duration of the study is 24-30 months. Inclusion criteria are: 18 to 50 years of age, with primary or secondary infertility, subjected to endometrial preparation in a modified natural cycle for transfer of a genetically euploid blastocyst, from their own oocyte or oocyte donation, with a normal uterine cavity. Exclusion criteria are: uterine or endometrial disease (e.g., multiple myomatosis, severe adenomyosis, Asherman syndrome, refractory endometrium), conditions that prevent correct ultrasound assessment (tilted uterus), or a history of recurrent implantation failure or repeated miscarriages.

02

Conditions studied

  • Infertility Due to Nonimplantation

Browse trials for

03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 206 is close to the median of 200 across 714 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Instituto Bernabeu is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

206 Women between 18-50 years, with primary or secondary infertility, undergoing fertility treatment that includes endometrial preparation in a modified natural cycle for transfer of previously analyzed frozen and euploid embryos.

Inclusion criteria

  • Aged 18 to 50 years
  • Primary or secondary infertility
  • Normal uterine cavity
  • Endometrial preparation in a modified natural cycle for single embryo transfer
  • Embryo in blastocyst state from own oocyte or oocyte donation cycles, who had normal results on preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy.

Exclusion criteria

Exclusion Criteria:

  • Uterine or endometrial disease (multiple myomatosis [>3 fibroids of > 3 cm], adenomyosis, Asherman syndrome)
  • Difficulties in correctly measuring endometrial thickness due to a retroverted or tilted uterus
  • History of recurrent implantation failure (3 or more transferred blastocysts of good quality, from their own oocyte [\<35 years] or oocyte donation); recurrent early Pregnancy Loss (the loss of two or more pregnancies before 10 weeks of gestational age.
  • Suboptimal endometrial response (endometrium \< 6 mm on the day of ovulation triggering).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
206 participants (estimated)
Target follow-up
4 Months
Patient registry
Yes

Groups and cohorts

  • exposed or "compaction" group

    103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).

    Other: Observational non intervention study

  • non-exposed "non-compaction" group

    103 women with similar or greater endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).

    Other: Observational non intervention study

Interventions

  • OtherObservational non intervention study

    An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate

    Presence of an intrauterine pregnancy with positive embryo heartbeat as seen by sonography at 8-10 weeks gestational age.

    Time frame: 8-10 weeks gestational age.

Secondary outcomes

  1. Biochemical pregnancy loss

    Spontaneous pregnancy demise based on decreasing serum b-hCG levels, without an ultrasound evaluation.

    Time frame: 9-10 days after the embryo transfer.

  2. Clinical pregnancy

    A pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy.

    Time frame: 5-6 weeks gestational age.

  3. Ectopic pregnancy

    ultrasonic or surgical visualization of a pregnancy outside of the endometrial cavity.

    Time frame: 5-8 weeks gestational age.

  4. Early pregnancy loss

    spontaneous pregnancy demise before 10 weeks of gestational age (before 8th developmental week).

    Time frame: 5-10 weeks gestational age.

07

Study locations

1 of 1 sites recruiting
  • Instituto Bernabeu
    Madrid, 28001, Spain
    Recruiting
08

References and documents

Study documents

  • Informed consent form · Jul 29, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05960370
Lead sponsor
Instituto Bernabeu
Collaborators
Universidad Miguel Hernandez de Elche
Responsible party
Dr. Esperanza de la Torre Perez (Gynecologist, Instituto Bernabeu) — Principal investigator
First posted
Jul 25, 2023
Start date
Jun 15, 2022
Primary completion
Jun 15, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Oct 3, 2024

Study contacts

Esperanza E de la Torre Pérez, Gynecologist
Contact
espe_delatorre@hotmail.com
+34625072082
Juan Carlos J Castillo Farfan, Doctor
Contact
jcastillo@institutobernabeu.com
+34650562634
Juan Carlos J Castillo Farfan, Doctor
study director · Instituto Bernabeu Alicante

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion